Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews (2018)
- Authors:
- Autor USP: HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- DOI: 10.1080/17512433.2018.1511424
- Subjects: TRANSTORNOS DA ANSIEDADE; ANSIOLÍTICOS; SEROTONINA
- Keywords: 5-HT2A receptor; Anxiety disorders; Ayahuasca; Dimethyltryptamine; Lysergic acid diethylamide; Mood disorders; Psilocybin; Substance-use disorders
- Language: Inglês
- Imprenta:
- Source:
- Título: Expert Review of Clinical Pharmacology
- ISSN: 1751-2433
- Volume/Número/Paginação/Ano: v. 11, n. 9, p. 889-902, 2018
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SANTOS, Rafael G. dos et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, v. 11, n. 9, p. 889-902, 2018Tradução . . Disponível em: https://doi.org/10.1080/17512433.2018.1511424. Acesso em: 10 jan. 2026. -
APA
Santos, R. G. dos, Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11( 9), 889-902. doi:10.1080/17512433.2018.1511424 -
NLM
Santos RG dos, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews [Internet]. Expert Review of Clinical Pharmacology. 2018 ; 11( 9): 889-902.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1080/17512433.2018.1511424 -
Vancouver
Santos RG dos, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews [Internet]. Expert Review of Clinical Pharmacology. 2018 ; 11( 9): 889-902.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1080/17512433.2018.1511424 - Cognition in at-risk mental states for psychosis
- Amino acids in schizophrenia: glycine, serine and arginine
- Effects of the natural β-carboline alkaloid harmine, a main constituent of Ayahuasca, in memory and in the hippocampus: a systematic literature review of preclinical studies
- Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
- O que o psiquiatra precisa saber sobre a iloperidona
- O que o psiquiatra precisa saber sobre a cariprazina
- Novos medicamentos
- Como eu faço prevenção de recaída na esquizofrenia
- O outro lado da Ayahuasca. [Entrevista a Ricardo Zorzetto]
- Antibiótico melhora funções cerebrais.[Depoimento a Rubens Zaidan]
Informações sobre o DOI: 10.1080/17512433.2018.1511424 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
